Intralytix, Inc.

Intrlytix Inc.

Zoctis Services LLC

Zoctis Server LLC

Zoetis Products LLC

Alpharma, LLC

Alexander Sulakvelidze

Gary R Pasternack

J Glenn Morris

Zemphira Alavidze

Torrey C Brown

Jeremy Mathers

Shanmuga Sozhamamnnan

Torrey Brown

Gary Pasternack

The present invention is directed to isolated bacteriophages having specificity and lytic activity against strains ofspecies, methods of using the bacteriophages, progeny and derivatives derived therefrom, to control the growth ofspecies in various settings (e.g., food safety, sanitation, modulating microbiome, prebiotics, probiotics).

bacteriophages and uses thereof

Disclosed herein are purified bacteriophage preparations that effectively lyse a plurality ofstrains. In one embodiment, a purified bacteriophage preparation includes four or more-specific bacteriophage, wherein each bacteriophage has lytic activity against at least fivespecies strains. In another embodiment, the purified bacteriophage preparation includes five or more-specific bacteriophage.

Bacteriophage preparations and methods of use thereof

Disclosed herein are purified bacteriophage preparations that effectively lyse a plurality ofspecies strains, in particularand. In one embodiment, a purified bacteriophage preparation includes four or more-specific bacteriophage, wherein each bacteriophage has lytic activity against at least fivespecies strains. In another embodiment, the purified bacteriophage preparation includes five or more-specific bacteriophage. The invention also relates to the use of purified bacteriophage preparation in combination with antibiotics for the treatment of animals including poultry. The invention also relates to the use of the purified bacteriophage preparations as treatments effective against antibiotic-resistant strains of

Disclosed herein are purified bacteriophage preparations that effectively lyse a plurality ofstrains. In one embodiment, a purified bacteriophage preparation includes four or more-specific bacteriophage, wherein each bacteriophage has lytic activity against at least fivestrains. In another embodiment, the purified bacteriophage preparation includes five or more-specific bacteriophage.

Bacteriophage preparations and method of use thereof

The present invention is directed to isolated bacteriophages having specificity and lytic activity against strains ofspecies, methods of using the bacteriophages, progeny and derivatives derived therefrom, to control the growth ofspecies in various settings (e.g., food safety, sanitation, probiotics).

Salmonella bacteriophage and uses thereof

The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.

Reduction in bacterial colonization by administering bacteriophage compositions

The present invention is directed to isolated bacteriophage having strong lytic activity against strains ofin particular, MRSA, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth ofin various settings.

[object Object]

The present invention is directed to isolatedbacteriophage, and methods of usingbacteriophage, or polynucleotides and polypeptides derived therefrom, to control the growth or contamination of food products by. The present invention also contemplates the use ofbacteriophage, and polynucleotides and polypeptides derived therefrom, for the treatment of host infections or environmental contamination by

The present invention is directed to isolated bacteriophage having strong lytic activity against strains ofO157:H7, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth ofO157:H7 in various settings.

The present invention is directed to isolated bacteriophage having strong lytic activity against strains of, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth ofin various settings.

Growing community of inventors

Towson, MD, United States of America

Alexander Sulakvelidze